Astrazeneca (AZN) Income from Continuing Operations (2009 - 2026)

Astrazeneca's Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 3914000000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 15.05% year-over-year to 3914000000.0; the TTM figure through Mar 2026 stood at 12914000000.0 (up 38.96% YoY), while the FY2025 annual figure was 10233000000.0, up 45.33% from the prior year.
• Income from Continuing Operations was 3914000000.0 for Q1 2026 at Astrazeneca, up from 2629000000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 3914000000.0 in Q1 2026 to a low of 247000000.0 in Q2 2022.
• Historically, Income from Continuing Operations has averaged 2023882352.94 across 5 years, with a median of 2088000000.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations slumped 67.67% in 2022, then surged 745.34% in 2023.
• A 5-year view of Income from Continuing Operations shows it stood at 778000000.0 in 2022, then grew by 15.3% to 897000000.0 in 2023, then soared by 85.73% to 1666000000.0 in 2024, then surged by 57.8% to 2629000000.0 in 2025, then soared by 48.88% to 3914000000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 3914000000.0 (Q1 2026), 2629000000.0 (Q4 2025), and 3244000000.0 (Q3 2025), per Business Quant data.